���ӽ紫ý

A blood test for Alzheimer’s Disease a game-changer for patients and their families.

As current drugs fall short, companies are exploring new targets to treat the neurodegenerative disease

For decades, diagnosing Alzheimer’s disease (AD) has required access to specialist memory clinics, neuroimaging or invasive cerebrospinal fluid (CSF) testing. That paradigm is starting to shift. In 2025, the US Food and Drug Administration (FDA) cleared the first blood-based biomarker tests intended to aid the assessment of AD.  

A new Nevada law prohibits schools from using AI to perform the work of school counselors and other professionals involved in the mental health of students. We discuss the pros and cons of using AI in mental health work, and we meet the humanoid robots creators say can serve as companions. Then, a discussion on reducing Alzheimer’s disease risks in Your Brain Health Matters.

Today, Global Alzheimer’s Platform Foundation® (GAP) and Clinical Neurology Specialists (CNS) announced their collaboration to accelerate Alzheimer’s disease research in Las Vegas. CNS has joined the GAP-sponsored study, Bio-Hermes-002, a unique, observational platform study that compares blood-based and digital biomarkers to generate data that may help predict, detect and diagnose Alzheimer’s disease and related dementias. This is a transformative, international study, but CNS is the only Las Vegas research site participating.

A study on Ozempic’s impacts on Alzheimer’s disease didn’t have the results scientists hoped for. We talk to ���ӽ紫ý’s Dr. Jeffrey Cummings on the research and what’s next. Also from ���ӽ紫ý: a look at how a “new” species of an ancient human ancestor can help shape our view on evolution. We end with a fun story on “Silver Belle”... the first tree from Nevada to serve as the U.S. Capitol Christmas Tree!

Over the past few years, scientists have learned that Ozempic and related drugs developed to treat Type 2 diabetes can improve the health of the liver, kidney and heart. Is it such a stretch to think they could also treat neurological disorders? Perhaps — at least when it comes to Alzheimer’s disease.

Alzheimer's patients treated with the GLP-1 receptor agonist semaglutide (Rybelsus) in two phase III trials showed no significant improvement in cognitive or functional decline over 2 years compared with placebo, according to new data presented at the Clinical Trials on Alzheimer's Disease (CTAD) annual meeting.